This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Acumen Pharmaceuticals, Inc.

Drug Names(s): ACU-193

Description: ACU-193 is an antibody with selective affinity against soluble AB oligomers / ADDLs (amyloid beta derived diffusible ligands).

Discovered by Acumen's founders, ADDLs are soluble oligomeric assemblies of amyloid beta 1-42 protein. They are implicated as the molecular structures that cause Alzheimer's disease and trigger early memory-related disorders. Antibodies targeting ADDLs have prevented and also reversed memory deficits in animal models.

Deal Structure: Acumen and Merck
In January 2004, Acumen entered into a research collaboration and license agreement with Merck to research and develop disease-modifying therapeutic drugs for Alzheimer's disease and other memory related disorders. Merck has acquired the worldwide exclusive rights to Acumen's ADDL technology for monoclonal antibodies and vaccines.

Under the terms of the agreement, Acumen will receive an upfront payment and annual research funding, and will be eligible to receive $48 million in research, development and approval milestones for the first antibody product that is commercialized. Acumen will also be eligible to receive equivalent milestone payments for the research, development and approval of vaccine products. Merck will fund research and development and will have exclusive responsibility for commercializing collaboration products. Merck will pay to Acumen royalties on the sale of products from the collaboration and milestones payments for the...See full deal structure in Biomedtracker

ACU-193 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug